Back to top
more

Humana (HUM)

(Real Time Quote from BATS)

$304.59 USD

304.59
412,190

-1.31 (-0.43%)

Updated Apr 29, 2024 12:09 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (203 out of 252)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Investors Should Hold Humana (HUM) in Portfolio

by Zacks Equity Research

Humana (HUM) remains well-poised for growth on the back of an expanding Medicare Advantage membership, upgraded health plan offering suite and solid cash reserves.

Humana (HUM) to Provide In-home Care With Primary Care Anywhere

by Zacks Equity Research

Humana (HUM) enhances its CenterWell brand with the launch of Primary Care Anywhere.

Why Humana (HUM) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Debasmita Chatterjee headshot

5 HMO Stocks to Watch Amid Growing Premiums & Membership

by Debasmita Chatterjee

Expanding customer base, contract wins and a rapidly growing aging U.S. population will likely drive the performances of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from favorable industry trends.

Humana (HUM) to Bring Enhanced Kidney Care to MA Members

by Zacks Equity Research

Humana (HUM) makes Interwell's extensive resources available to its MA members grappling with CKD and ESKD, and hence bring about better health outcomes for them.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Encompass Health's (EHC) Q2 Earnings Beat, '23 EPS View Raised

by Zacks Equity Research

Encompass Health's (EHC) Q2 results reflect a growing patient base and improved net patient revenue per discharge. Management anticipates 2023 adjusted EPS within $3.31-$3.53, up from the earlier view of $2.94-$3.23.

Company News for Aug 3, 2023

by Zacks Equity Research

Companies in The News Are: VRTX, DVN, AFL, HUM

Humana (HUM) Q2 Earnings Beat on Strong Individual MA Unit

by Zacks Equity Research

Humana's (HUM) Q2 results gain from strong pharmacy revenues and revenue growth within the Insurance segment, partly offset by higher benefits expenses.

Private Sector Jobs Come in Higher Than Expected

by Zacks Equity Research

Private Sector Jobs Come in Higher Than Expected.

Mark Vickery headshot

ADP Jobs +324K Still Higher than Expected; CVS, KHC, HUM Report

by Mark Vickery

ADP Chief Economist Nela Richardson said, "The economy is doing better than expected... we continue to see a slowdown in pay growth without broad-based job loss."

Humana (HUM) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Humana (HUM) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Humana (HUM) Surpasses Q2 Earnings Estimates

by Zacks Equity Research

Humana (HUM) delivered earnings and revenue surprises of 0.68% and 0.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Humana (HUM) Q2 Earnings Beat on Strong Pharmacy Business?

by Zacks Equity Research

Humana's (HUM) second-quarter results are likely to reflect rising premiums and investment income.

Aparajita Dutta headshot

5 Low-Leverage Stocks to Buy Following the Fed Rate Hike

by Aparajita Dutta

The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You may buy HUM, TEX, ARI, ATO and TNK.

Centene (CNC) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Centene (CNC) delivered earnings and revenue surprises of 2.44% and 3.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Molina (MOH) Q2 Earnings Beat on High Premiums, '23 View Raised

by Zacks Equity Research

Molina Healthcare's (MOH) second-quarter results are aided by increased membership, and Medicaid and Medicare strength.

Humana (HUM) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Humana (HUM) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Humana (HUM) closed at $454.34, marking a +0.2% move from the previous day.

Here's What to Expect From Acadia Healthcare's (ACHC) Q2 Earnings

by Zacks Equity Research

Acadia Healthcare's (ACHC) Q2 results are likely to reflect increased patient volumes across its U.S. operations, partly offset by a higher expense base.

Does Humana (HUM) Have the Potential to Rally 28.97% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 29% upside potential for Humana (HUM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Will High Medical Costs Hurt Molina Healthcare's (MOH) Q2 Earnings?

by Zacks Equity Research

Molina Healthcare's (MOH) Q2 results are likely to reflect the membership growth in its Medicaid and Medicare business units, partly offset by an elevated medical cost level.

Are Investors Undervaluing Humana (HUM) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.